NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs

The Comprehensive Department of China’s National Medical Products Administration (NMPA) has released the Measures for the Implementation of Drug Market Exclusivity (Draft for Comment), proposing a unified exclusivity regime that would grant 7, 5, or 4 years of protection for rare disease drugs and up to 2 years for pediatric drugs. Public comments are open through 18 Nov 2026. The Measures would apply across traditional Chinese medicines, chemical drugs, and therapeutic biological products, aiming to meet public demand for medicines and encourage innovation in rare disease treatments and pediatric drug development.

Regulatory Milestone

Proposed Exclusivity Tiers – Rare Disease Drugs

Proposed Exclusivity Tiers – Pediatric Drugs

Key Provisions & Procedural Rules

• Approval Freeze: During the exclusivity period, the NMPA will not approve marketing applications or supplemental applications for the same variety of drug submitted by other applicants.
• Application Procedure: Market exclusivity must be applied for together with the drug registration application; the Center for Drug Evaluation (CDE) will review it alongside the technical review.
• One Designation per Drug: Where a product qualifies for both rare disease and pediatric exclusivity, the applicant may claim only one.
• Indication‑Level Calculation: Where different indications of the same drug obtain exclusivity successively, each indication’s exclusivity period is calculated separately.
• Interplay with Data Protection: If a pediatric drug’s exclusivity overlaps the drug trial data protection period, exclusivity begins on the second day after data protection expires; during that protection window, same‑variety drugs that independently generate their own data may still be approved if conditions are met.
• Supply Commitment: Rare disease applicants must commit to ensuring market supply and, barring force majeure, avoid discontinuation or shortages. Failure to honor the commitment allows the NMPA to terminate the market exclusivity.

Market Impact & Outlook

• Orphan Drug Incentives: The proposed 7‑year top tier mirrors orphan‑drug exclusivity benchmarks in mature markets such as the U.S., giving sponsors of first‑launched rare disease therapies a materially longer protected runway in China.
• Lifecycle Management: Indication‑by‑indication calculation enables sponsors to layer exclusivity across successive rare disease and pediatric indications of the same molecule — a new lever for lifecycle strategy.
• Pediatric Reformulation Opportunity: The 1‑year tiers for new pediatric dosage forms and specifications lower the development threshold, likely encouraging reformulation pipelines for already‑marketed drugs.
• Generics & Biosimilar Timing: The 4‑year tier for generics and biological products of overseas rare disease drugs creates a defined, if delayed, market‑entry window; launch planning must now factor exclusivity stacking and data‑protection sequencing.
• Compliance Watch: Exclusivity is conditional — the supply commitment and termination clause turn protection into a two‑way obligation, making commercial supply readiness a regulatory risk factor for rare disease sponsors.

Forward‑Looking Statements
This brief describes a draft regulation open for public comment. The final Measures may differ materially from the draft in scope, exclusivity periods, and procedures, and the timing of issuance and implementation remains uncertain. No approval outcomes or commercial expectations should be inferred from this draft.-Fineline Info & Tech